

## Article

## FormyIBODIPYs: Privileged Building Blocks for Multicomponent Reactions. The case of the Passerini Reaction

Diana E. Ramírez-Ornelas, Enrique Alvarado-Martínez, Jorge Bañuelos, Iñigo Lopez Arbeloa, Teresa Arbeloa, Héctor M. Mora-Montes, Luis A. Pérez-García, and Eduardo Peña-Cabrera

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.5b02893 • Publication Date (Web): 11 Mar 2016 Downloaded from http://pubs.acs.org on March 12, 2016

## Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# FormylBODIPYs: Privileged Building Blocks for Multicomponent Reactions. The case of the Passerini Reaction

Diana E. Ramírez-Ornelas,<sup>†</sup> Enrique Alvarado-Martínez,<sup>†</sup> Jorge Bañuelos,<sup>\*,¥</sup> Iñigo López Arbeloa,<sup>¥</sup> Teresa Arbeloa,<sup>¥</sup> Héctor M. Mora-Montes,<sup>§</sup> Luis A. Pérez-García<sup>§</sup> and Eduardo Peña-Cabrera<sup>\*,†</sup>

<sup>†</sup> Departamento de Química, Universidad de Guanajuato, Col. Noria Alta S/N,

Guanajuato, Gto. 36050 Mexico.

<sup>¥</sup>Departamento de Química Física, Universidad del País Vasco-EHU, Apartado 644,

48080, Bilbao, Spain.

<sup>§</sup> Departamento de Biología, Universidad de Guanajuato, Col. Noria Alta S/N,

Guanajuato, Gto. 36050 Mexico.

E-mail: jorge.banuelos@ehu.es, eduardop@ugto.mx

#### Abstract

Eleven formyl-containing BODIPY dyes were prepared by means of either the Liebeskind-Srogl cross-coupling reaction or the Vilsmeier reaction. These dyes were used as components in the Passerini reaction to give highly substituted BODIPY dyes. A joined spectroscopic and theoretical characterization of the synthesized compounds was conducted to unravel the impact of the structural rigidity/flexibility on the photophysical signatures. These dyes were tested as fluorescent trackers for phagocytosis. Additionally, they proved to be useful to stain different blood cells with intense and stable signal at a very low exposure time.

#### Introduction

> Multicomponent reactions (MCR) are ideal processes to generate chemical complexity in an efficient and atom-economical way.<sup>1</sup> Several applications of these reactions can be found in the literature. For example, they have been used to prepare nitrogen-enriched heterocyclic scaffolds,<sup>2</sup> imidazo[1,2-a]pyridines,<sup>3</sup> dihydropyrroles,<sup>4</sup> substituted 1*H*chromeno[2.3-d]pyrimidine-5-carboxamides.<sup>5</sup> imidazoles,<sup>6</sup> aminoacids.<sup>7</sup> 1.4benzodiazepine-2.5-diones.<sup>8</sup> and *N*-substituted diketopiperazines.<sup>9</sup> just to mention a few. It is clear that in the majority of the examples reported, aldehydes play a crucial role, and therefore, it is of paramount importance to be able to prepare the aldehyde component for the specific application sought after. Many of the complex structures that are constructed after MCR's possess important properties, such as cytotoxic activity against the human lung cancer cell line,<sup>10</sup> antimicrobial and antioxidant,<sup>11</sup> aggregation-induced emitters,<sup>12</sup> anti-tumor agents,<sup>13</sup> just to mention a few examples. An additional property that would be highly desirable for the MCR adducts to have is fluorescence. This property would provide plenty of information about processes that take place on and inside cells.<sup>14</sup> Some groups have devoted considerable efforts to prepare fluorescent molecules using MCR. For instance, Wang et al. have prepared polysubstituted 2,6-dicyanoanilines and iminocumarins,<sup>15</sup> Balakirey and co-workers developed fluorescent pharmacophores in droplet arrays,<sup>16</sup> Müller and collaborators prepared fluorescent indolizines,<sup>17</sup> In a pioneering paper, Vendrell, Lavilla, and co-workers reported several isonitrile-based MCR to prepare fluorescent probes for *in vivo* imaging of phagocytic macrophages.<sup>18</sup> They chose to

use a BODIPY<sup>19</sup> (borondipyrromethene)-containing isonitrile **1**, to carry out a Passerini,<sup>20</sup> a Bienaymé–Blackburn–Groebcke,<sup>21</sup> and variants of the Ugi reaction.<sup>22</sup>



Despite the fact that such work was a ground-breaking contribution, no variation of the functional groups in **1** was presented. In that regard, another good candidate for MCRs where the final product would be fluorescent (FMCR), is a formyl-containing BODIPY of the type **2** or **3** (Figure 1).



Figure 1. Formyl-containing BODIPYs suitable for FMCR.

#### **Results and discussion**

Our laboratory has devised a versatile method to prepare, in a very straightforward way, a series of *meso*-formylhet(aryl)BODIPYs using the Liebeskind-Srogl coupling reaction starting from commercially available Biellmann BODIPYs  $A-C^{23}$  (Scheme 1).<sup>24</sup> In those contributions, we underscore the fact that, with this methodology, the preparation of formyl-containing BODIPYs becomes trivial and one does not have to face the

regioselectivity issues posed by the typical Lindsey methodology that entails the condensations of a benzaldehyde with pyrrole under acidic conditions.

## Scheme 1. Application of the Liebeskind-Srogl coupling in the synthesis of *meso*formylhet(aryl)BODIPYs from the Biellmann BODIPYs A-C



The synthesis of 2-formylBODIPYs is well documented in the literature.<sup>25</sup> In this contribution, we demonstrate the applicability of several highly functionalized formyl-containing BODIPYs in the Passerini reaction.

FormylBODIPYs of the type **2** were prepared according to Scheme 1, and the results are shown in Scheme 2.

## Scheme 2. FormylBODIPYs of the type 2 synthesized<sup>a</sup>



<sup>*a*</sup> Conditions: Biellmann BODIPY (1 equiv), formylboronic acid (3 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (2.5%), TFP (7.5%), CuTC (3 equiv), THF, 55 °C.

A more functionalized formylBODIPY **2f** was prepared according to Scheme 3 using our recently reported orthogonal reactivity of BODIPY **D**.<sup>26</sup>

### Scheme 3. Synthesis of BODIPY 2f



BODIPYs of the type **3** were prepared according to the reported method (Scheme 4).

## Scheme 4. Synthesis of 8-(het)aryl-2-formylBODIPYs<sup>*a,b*</sup>



<sup>*a*</sup> Isolated yields. <sup>*b*</sup> Conditions: 1) BODIPY (1 equiv), POCl<sub>3</sub>/DMF (160 equiv), DCE (10 mL), 80 °C. 2) sat. aq. K<sub>2</sub>CO<sub>3</sub>, 1 h.

FormylBODIPYs **2a-f** and **3a-e** were utilized as components in the Passerini reaction along with benzoic acid and *t*-butyl isonitrile. The results are illustrated in Scheme 5.



Scheme 5. Synthesis of the Passerini BODIPY adducts<sup>*a*</sup>

<sup>*a*</sup> Isolated yields. Conditions: formylBODIPY (1 equiv), benzoic acid (3 equiv), *tert*-butyl isocyanide (3 equiv), CH<sub>2</sub>Cl<sub>2</sub>/ H<sub>2</sub>O (1:1/ 1mL), r.t.

<sup>b</sup> The reaction took 48 h for this substrate.

In general, the reaction is operationally simple. In all cases, except for **5b**, the reaction went to completion in 24 h. A general trend was observed; the yields were higher when the formyl group was located on the 8-het(aryl) ring (compounds **4a-f**). When the formyl group was connected directly to the BODIPY core, the yields were lower (except for **5b**) presumably because of a diminished electrophilicity of the aldehyde group due to the electron-releasing properties of the BODIPY unit at position 2 (Figure 2).



Figure 2. Decreased electrophilicity of the formyl group at position 2.

Additionally, substituents on the *meso*-aryl group of 2-formylBODIPYs also affected the chemical yield. When the *meso*-aryl ring contained electron-withdrawing groups, the yields dropped (**5c** and **5d**).

## **Spectroscopical properties**

The photophysical signatures of those BODIPYs resulting from the MCR (**4a-f** and **5a-e**, in Scheme 5) are summarized in Table 1. Overall, the absorption properties of the BODIPY are hardly affected by the 8-arylation, owing to the low resonance interaction between their electronic clouds, at least in the ground state. Indeed, the computing molecular orbitals (see HOMO of **5a-b** in Figure 3) predict almost no extension of the delocalized  $\pi$ -system from the indacene core to the *meso*-aryl fragment. However, the fluorescence response of the BODIPYs bearing an unhindered 8-phenyl (**4a** and **5a**) is rather low (lower than 4% with lifetime of hundred of picoseconds) owing to a remarkable high internal conversion probability caused by the free rotational motion of such ring (energy barrier around 12 kcal/mol in Figure 4).<sup>24b,1</sup> Moreover, the LUMO of **5a** places electronic density at the 8-aryl upon excitation (Figure 3), suggesting more degree of electronic coupling with the BODIPY, which eventually could lead to a strong interaction and cause a severe distortion of the chromophore planarity (Figure 4).<sup>27</sup> Indeed, such non-radiative pathways are fully suppressed when the aryl is locked in an orthogonal arrangement by methylation at its *ortho* positions (**5b**). The high rotational barrier of the mesityl group (around 45 kcal/mol) disables the free motion of the aryl and the bright fluorescence efficiency characteristic of BODIPYs is recovered (82% with long lifetimes, 6.5 ns in Table 1).<sup>28</sup> Accordingly, the contribution of the aryl to the LUMO orbital is almost negligible since the electronic coupling is hampered.



**Figure 3**. Computed frontier molecular orbitals for the representative compounds **5a-b** and **5e**. The corresponding dihedral angle between the indacene and the aryl planes from the optimized ground and excited state geometries are also included.



Figure 4. Computed energy surfaces for the rotation of the 8-phenyl (5a) and 8-thenyl (5e) derivatives with regard to the indacene plane in AcOEt. The corresponding geometries at the energy maximum and minimum are also shown.

The simple alkylation at the  $\alpha$  positions (3 and 5) of pyrroles (see **4b** and **4c** *vs* **4a** in Scheme 5) leads to a bathochromic shift of the spectral bands and a slight increase of both, the absorption probability (with values up to 82400 M<sup>-1</sup> cm<sup>-1</sup>) and the fluorescence efficiency (Figure 5), which is ascribed to a more planar structure and thereby a more aromatic chromophore.<sup>29</sup> Whereas the *para*-functionalization of the 8-phenyl (bromine **5c** and trifluoromethyl **5d**) does not alter the photophysics of the BODIPYs (being identical to the **5a** counterpart, Scheme 5), it is noteworthy the  $\beta$ -bromination (position 2 and 6) effect (**4f**, Figure 5). As a common rule, this heavy atom shifts bathochromically the spectral bands and increases the intersystem crossing.<sup>30</sup> As a consequence, the direct linkage of the bromine heteroatom usually quenches the fluorescence deactivation of the

BODIPY. However, in the herein reported BODIPYs with unlocked 8-rings the bromination provides improved fluorescence efficiencies (from 4% in **4b** to 25% with lifetime of 2.45 ns, Table 1). Thus, the deleterious effect of the aryl free motion can be counteracted not only by steric hindrance, but also with electronegative atoms which remove electronic density from the *meso* position.<sup>31</sup>

**Table 1.** Photophysical properties of the resulting BODIPY derivatives after MCR (**4a-f** and **5a-e**, Scheme 5) from the corresponding formylated dyes in ethyl acetate; absorption  $(\lambda_{ab})$  and fluorescence wavelength  $(\lambda_{fl})$ , molar absorption  $(\varepsilon_{max})$ , fluorescence quantum yield ( $\phi$ ), lifetime ( $\tau$ ), radiative ( $k_{fl}$ ), and non-radiative ( $k_{nr}$ ) deactivation rate constants.

	$\lambda_{ab}$	$\epsilon_{max} \cdot 10^{-4}$	$\lambda_{\mathrm{fl}}$	¢	τ	$k_{\rm fl}$ ·10 <sup>-7</sup>	$k_{nr} \cdot 10^{-9}$
	(nm)	$(M^{-1}cm^{-1})$	(nm)		(ns)	$(s^{-1})$	$(s^{-1})$
<b>4</b> a	499.5	5.8	518.0	0.01	0.20	9.62	7.6
4b	509.5	8.2	525.0	0.04	1.05	3.81	0.9
4c	510.5	7.3	526.0	0.04	0.93	4.30	1.0
4d <sup>*</sup>	509.5	4.6	530.0	-	0.09(68%)-0.56(32%)	-	-
			657.0	-	0.30		
<b>4</b> e <sup>*</sup>	520.5	5.9	549.0	-	0.15(75%)-0.37(25%)	-	-
			645.0	-	0.35		
4f	540.0	7.5	561.0	0.25	2.45	10.2	0.3
5a	505.0	4.7	525.5	0.03	0.34	10.0	2.8
5b	505.5	6.6	522.0	0.82	6.51	12.6	0.03
5c	507.0	5.1	529.5	0.02	0.24	8.33	4.1
5d	509.5	5.1	530.5	0.02	0.21	9.52	4.7
5e <sup>*</sup>	513.5	4.1	549.0	-	0.18(70%)-0.47(30%)	-	-
			646.0	-	0.50		

<sup>\*</sup>In the BODIPYs bearing and 8-thienyl fragment (**4d-e** and **5e**) the fluorescence quantum yield is not given because two overlapped emission bands are detected simultaneously.



Figure 5. Absorption and fluorescence spectra of the compounds bearing unhindered 8-tolyl (4a), with alkyls at positions  $\alpha$  (methyl 4b and ethyl 4c) and bromines at positions  $\beta$  (4f) in diluted solutions of ethyl acetate.

The presence of the thienyl group at the *meso* position (**4d-e** and **5e**) does not affect the position of the absorption band (Table 1), confirming again the absence of electronic coupling of aromatic rings at such positions in the ground state (Figure 3). It should be noticed that thiophene leads to effective resonance interactions to develop red-emitting BODIPYs but at position  $\alpha$  or  $\beta$  of the chromophoric core or even fused to it.<sup>32</sup> However, its high electron releasing ability in the highly sensitive *meso* position induces significant changes in the emission spectrum (Figure 6). The fluorescence signal from the locally excited (LE) state of the BODIPY (530-550 nm) is drastically quenched and a new broad band appears at 645-655 nm, which is ascribed to the population of an intramolecular charge transfer state (ICT) from the donor thienyl group to the acceptor BODIPY.<sup>33</sup> The intensity of this new emission markedly changes with the solvent polarity. Thus, it decreases progressively as the solvent polarity is increased. In these media the charge separation is further stabilized (low probability of charge recombination) and the non-radiative deactivation from the ICT prevails over the radiative one.<sup>34</sup> As a consequence,

in the more polar solvent the fluorescence signal is hardly detected. As a matter of fact, note that the additional presence of the inductive donor methyl groups at  $\alpha$  positions (4e) leads to a less intense emission from the ICT than that from the LE, owing to the above claimed higher stabilization of the ICT state, whereas in 4d (non-alkylated chromophore) the ICT band is most intense than the emission from the LE state (Figure 6). It is remarkable that this solvent switchable new emission depends on the geometrical arrangement of the thienyl fragment, since when it is disposed fully orthogonal (by the steric hindrance at the adjacent positions 1 and 7) with regard to the BODIPY core, the ICT is also operative but no new emission bands are detected.<sup>35</sup> Moreover, it seems that the thienyl twisting is involved in the ICT population probability. This ring at the *meso* position contributes to the LUMO (see compound 5e in Figure 3), as expected due to its rotational freedom (rotational barrier of 5.5 kcal/mol, lesser than **5a** owing to the smaller thiophene ring, Figure 4), but what is more striking is the increase of the dihedral angle upon excitation (from 45° to 65°, Figure 3). Such more perpendicular orientation of the thienyl group in the excited state is in agreement with a twisted ICT (TICT).<sup>36</sup>



**Figure 6**. Fluorescence spectra of the compounds bearing 8-thienyl (**4d**-**e** and **5e**) and their corresponding analogues with 8-phenyl (**4a** and **5a**, respectively) in diluted solutions of ethyl acetate.

Finally, it should be stressed that the photophysics of the BODIPY are not affected by the bulky fragment generated after MCR either at the *para* position of the 8-phenyl group, or directly at the BODIPY 2-position since it is separated from the chromophoric core by a methine unit. Thus, the herein reported synthetic route is a cost-effective and straightforward method to design smart multichromophoric assemblies, from BODIPYs or other fluorophores with the required functionality, in which each fragment retains its molecular identity.

#### **Biological Essays**

We have tested the ability of the eleven BODIPYs herein described as possible probes for fluorescence microscopy using human phagocytic cells. First, we aimed to assess whether BODIPYs were suitable for tracking the fungal cell phagocytic processes in humanderived macrophages or not. After 3h of *Candida parapsilosis*-macrophage interaction BODIPYs were added and compounds **4b-e**, and , **5a-d** showed fluorescent signal in the green channel, nevertheless, it was quenched soon afterwards independent of the concentration used. In all cases, BODIPYs showed affinity to small-unidentified vesicles in the periphery of the macrophage but not to the phagolysosome, making unfeasible the tracking of the phagocytic process (Figure 7). Acridine orange staining was used as a control to assess phagocytosis.<sup>37</sup> Then, we further investigated the selectivity of the BODIPYs for different blood cells by performing a staining of monocytes, granulocytes and erythrocytes with them. Fluorescence remained constant during the whole observation period for all the compounds. Unlike the rest of the BODIPYs, compounds **4b** and **5b** preferentially stained the erythrocyte membrane, but the former caused cell crenation (Figure 8 A-D). The rest of the compounds mostly stained the cytoplasm but not the nuclei of monocytes and granulocytes cells (Figure 8 E-H). BODIPYs **4b** and **5b** exhibit an excellent performance at 75 ms of exposition; while the rest of the compounds worked better at 150 ms of exposition. The only exception was the BODIPY **4d** that needed 700 ms to achieve a defined signal.



**Figure 7**. Phagocytosis essays in bright field (A) and fluorescence microscopy (B) using the BODYPI 5b. The compound showed affinity to small-unidentified vesicles in the macrophage but not to the phagolysosome, making unfeasible the tracking of the phagocytic process. All the compounds exhibited similar results.



**Figure 8.** Compound **4b** stained the erythrocyte membrane causing crenation of the cells (A, B) unlike compound **5b** that also stained the membrane of the red blood cells without crenation (C,D). Similarly, both compounds stained mononuclear cells in a similar way (G,H). The rest of them, as compound **4e**, selectively stained the granulocytes but not the erithrocytes (E, F), and all of them stained the mononuclear cells.

We have described the synthesis of formyl-containing BODIPY derivatives using either the Liebeskind-Srogl cross-coupling reaction (6 examples) or the Vilsmeier reaction (5 examples). These dyes were used along with benzoic acid and *t*-butyl isocyanide in the Passerini reaction to produce 11 new dyes with rich functionality in a straightforward manner. The photophysical signatures of the formylated BODIPYs are ruled by the free motion of the 8-aryl and are kept after MCR reaction. Thus, this synthetic route is a straightforward method to design smart multichromophoric assemblies. These compounds are not suitable for phagocytosis tracking, nevertheless some of them can be used as fluorescent agents to identify blood cells in a very efficient manner since fluorescence remain constant and intense at a very low exposure time. Other examples of MCR with formylBODIPYs as well as other formyl-containing fluorophores are currently under investigation in our laboratories and the results will be reported shortly.

#### **Experimental Section**

**Synthesis and characterization:** Starting materials and reagents used in the preparation of BODIPYs are commercially available unless otherwise noted. The solvents were distilled and dried according to standard procedures before use. Unless stated otherwise, all reactions were performed without inert atmosphere in oven- and or flame-dried glassware. Reaction progress was monitored by TLC (silica gel plates with F-254 indicator) and the spots were visualized under UV light (254 or 365 nm). Flash column chromatography was performed using silica gel Kieselgel 60 (70-230 mesh) and mixture of ethyl acetate and hexanes as the eluent. Spectral data of the known compounds were in

accordance with the literature data. <sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired on spectrometers (500 or 400 MHz for <sup>1</sup>H and 125 or 101 MHz for <sup>13</sup>C) in deuteriochloroform (CDCl<sub>3</sub>) with either tetramethylsilane (TMS) (0.00 ppm <sup>1</sup>H, 0.00 ppm <sup>13</sup>C) or chloroform (7.26 ppm <sup>1</sup>H, 77.16 ppm <sup>13</sup>C) or as internal reference unless otherwise stated.<sup>38</sup> Data are reported in the following order: chemical shift in ppm, multiplicities (br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), sex (sextet), hep (heptet), m (multiplet), exch (exchangeable), app (apparent)), coupling constants *J* (Hz), and integration. Infrared spectra were recorded on a FTIR spectrophotometer. Peaks are reported (cm<sup>-1</sup>) with the following relative intensities: s (strong, 67-100%), m (medium 40-66%), and w (weak 20-39%). Melting points were determined and were uncorrected. HRMS samples were ionized by ESI+ and recorded via the TOF method.

8-Methylthiobodipys A-C,<sup>23</sup> compounds **2a-c**, **3a-3c**, **3e**,<sup>39</sup> and CuTC<sup>40</sup> were prepared according to the literature procedures.

## Spectroscopic measurements.

The photophysical properties were registered in diluted solutions (around  $2 \times 10^{-6}$  M) of ethyl acetate, using quartz cuvettes with optical pathway of 1 cm. UV-Vis absorption and fluorescence spectra were recorded on a spectrophotometer and a spectrofluorimeter, respectively. Fluorescence quantum yield ( $\phi$ ) was obtained by using the commercial PM567 dye as reference ( $\phi^{r} = 0.84$  in ethanol). Radiative decay curves were registered with the time correlated single-photon counting technique , equipped with a microchannel plate detector of picosecond time-resolution (20 ps). Fluorescence emission was monitored at the maximum emission wavelength after excitation by means of a laser. The fluorescence lifetime ( $\tau$ ) was obtained after the deconvolution of the instrumental response signal from the recorded decay curves by means of an iterative method. The goodness of the exponential fit was controlled by statistical parameters (chi-square, Durbin-Watson and the analysis of the residuals). Radiative (k<sub>fl</sub>) and non-radiative (k<sub>nr</sub>) rate constants were calculated as follows; k<sub>fl</sub> = $\phi/\tau$  and k<sub>nr</sub> = (1- $\phi$ )/ $\tau$ .

#### Computational modeling for representative compound 5a, 5b and 5e.

Ground state energy minimizations were performed using the Becke's Three Paramaters (B3LYP) Density Functional (DFT) method, whereas excited state geometry optimization was carried out using the *ab initio* Configuration Interaction Singles (CIS) method. The basis set was the double valence 6-31g\* (with a polarization function). The optimized geometry was taken as a true energy minimum using frequency calculations (no negative frequencies). Rotational energy barriers in the ground state were calculated from the potential energy surface, which was simulated by relaxed scans (steps of 10°) of the 8-phenyl, 8-thienyl and 8-mesityl twist with regard to the plane of the BODIPY core. The solvent effect (ethyl acetate) was considered in all the calculations by the Polarizable Continuum Model (PCM). All the calculations were performed in Gaussian 09, using the "arina" computational resources provided by the UPV-EHU.

## **Biological essays**

Peripheral blood mononuclear cells (PBMCs) were isolated from human blood as previously described.<sup>41</sup> The differentiation to macrophages was induced in serum-free

#### The Journal of Organic Chemistry

medium supplemented with 1 % (v/v) penicillin-streptomycin solution and 10 ng/mL recombinant human granulocyte-macrophage colony-stimulating factor, under incubation at 37 °C, 5 % (v/v) CO<sub>2</sub> for 6-7 days, replacing the medium every 2-3 days.<sup>42</sup> Macrophage infection with *Candida parapsilosis* yeast cells was performed at a MOI of 1:5, respectively. After 3 hours of incubation at 37 °C, 5 % (v/v) CO<sub>2</sub>, cells were treated with the BODIPY at a final concentration of either 1 µg/mL or 5 µg/mL in phosphate saline buffer (PBS) pH 7.4, letting the compound interact for 5 minutes at room temperature. Cells were washed and crystal violet solution (0.03% in PBS) was added for contrast. After 3 minutes, cells were washed again and placed onto slides to be inspected under fluorescence microscopy. For interaction of BODIPYs with monocytes, granulocytes and erythrocytes, cells were suspended in PBS containing the BODIPY at a final concentration of 1 µg/mL. After 15 minutes of incubation at room temperature, cells were washed twice with PBS and placed onto slides for inspection under the fluorescent microscopy.

All preparations were examined using a microscope. Acquisition of images was achieved by means of AxioVs40 V 4.6.1.0 software and a camera.

## Synthesis and characterization of compounds

*General Procedure for the Liebeskind-Srogl cross-coupling reaction (GP1).* An ovendry Schlenk tube, equipped with a stir bar, was charged with either 8-methylthiobodipy **A** or **B** (1.0 equiv.), the corresponding boronic acid (3.0 equiv.), and dry THF (0.03 *M*) under N<sub>2</sub>. The mixture was sparged with N<sub>2</sub> for 5 min, whereupon Pd<sub>2</sub>(dba)<sub>3</sub> (2.5 mol%), trifurylphosphine (7.5 mol%), and CuTC (3.0 equiv.) were added followed by 5 min N<sub>2</sub> purge. The reaction mixture was immersed into a pre heated oil bath at 55 °C. After TLC showed that the reaction went to completion, the reaction mixture was allowed to reach room temperature and was adsorbed on SiO<sub>2</sub>-gel. After flash-chromatography (SiO<sub>2</sub>-gel, EtOAc/hexanes gradient) purification, *meso* substituted BODIPYs were obtained as highly-colored solids.

General Procedure for the synthesis of  $\beta$ -FormylBODIPYs (*GP2*). In a roundbottomed flask equipped with a stir bar, DMF (3.0 mL, 39 mmol) and POCl<sub>3</sub> (3.0 mL, 32 mmol) were combined at 0 °C (ice-bath) under N<sub>2</sub> for 5 min. After warming to room temperature, the reaction mixture was further stirred for 30 min. Then, the corresponding  $\delta$ -(het)aryl-BODIPY (0.2 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (10 mL) was added to the reaction mixture. After raising the temperature at 80 °C, the reaction mixture was further stirred for 16 h, cooled to room temperature and slowly poured into a saturated aqueous K<sub>2</sub>CO<sub>3</sub> solution (100 mL) cooled in an ice bath. After warming to room temperature, the reaction mixture was further stirred for 1 h and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x50 mL). The organic layers were combined, washed with water (2x50 mL), dried with anhydrous MgSO<sub>4</sub>, filtered, and the solvent was removed under reduced pressure. The crude product was further purified by column chromatography on silica gel using a mixture of ethyl acetate and hexanes as eluent to give the  $\beta$ -formylated BODIPYs as dark red crystals.

General Procedure for the Passerini reaction (GP3). To a solution of corresponding formyl-BODIPY 2 or 3 (1.0 equiv.) in dichloromethane (0.5 mL), were sequentially added benzoic acid (3.0 equiv.) and *tert*-butyl isocyanide (3.0 equiv.) at room temperature, followed by addition of H<sub>2</sub>O (0.5 mL). The reaction mixture was stirred at room temperature for 24 h until completion (TLC monitoring). When the reaction was completed, the product was extracted with ethyl acetate, washed with brine (3x10 mL), and dried with anhydrous MgSO<sub>4</sub> and filtered. The solvent was removed under reduced pressure, and the crude product was purified by silica-gel column chromatography (EtOAc/hexane gradient) to obtain the desired product.

## The Liebeskind-Srogl cross-coupling reaction (LSCC) (Scheme 1).





According to GP1. **A** (70 mg, 0.2940 mmol, 1.0 equiv.), 5-formyl-2thienylboronic acid (138 mg, 0.8821 mmol, 3.0 equiv.), CuTC (168 mg, 0.8821 mmol, 3.0 equiv.), Pd<sub>2</sub>(dba)<sub>3</sub> (6.7 mg, 0.0074 mmol, 2.5 mol%), and tri-2-furylphosphine (5.1 mg, 0.0220 mmol, 7.5 mol%). The desired product was obtained as a dark red crystals (69 mg, 78 % yield); mp > 150°C (subl.); TLC (30% EtOAc/hexanes,  $R_f = 0.2$ ); IR (KBr, cm<sup>-1</sup>): 3111 (w), 3094 (w), 1672 (s), 1657 (s), 1548 (s), 1414 (s), 1386 (s), 1264 (s), 1212 (s), 1113 (s), 1076 (s), 969 (m), 776 (m), 666 (w), 630 (w), 583 (w); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.02 (s, 1H), 7.97 (s, 2H), 7.88 (d, J = 4.0 Hz, 1H), 7.58 (d, J = 4.0 Hz, 1H), 7.21 (d, J = 4.4 Hz, 2H), 6.60 (d, J = 4.0 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  182.9, 147.1, 145.6, 142.7, 137.5, 135.7, 134.4, 132.8, 131.6, 119.4; HRMS (ESI+): m/z calcd. for C<sub>14</sub>H<sub>10</sub>BF<sub>2</sub>N<sub>2</sub>OS [M+H]<sup>+</sup>, 303.0572; found 303.0574.



According to GP1. B (80 mg, 0.3006 mmol, 1.0 equiv.), 5-formyl-2thienylboronic acid (141 mg, 0.9018 mmol, 3.0 equiv), CuTC (172 mg, 0.9018 mmol, 3.0 equiv.), Pd<sub>2</sub>(dba)<sub>3</sub> (6.9 mg, 0.0075 mmol, 2.5 mol%), and tri-2-furylphosphine (5.2 mg, 0.0225 mmol, 7.5 mol%). The desired product was obtained as a dark red crystals (86 mg, 87 % vield); mp > 180 °C (subl.); TLC (30% EtOAc/hexanes,  $R_f = 0.3$ ); IR (KBr, cm<sup>-1</sup>): 3111 (w), 2924 (w), 2852 (w), 1668 (s), 1552 (s), 1493 (s), 1457 (s), 1280 (s), 1211 (s), 1152 (s), 1012 (m), 817 (m), 729 (m), 675 (w); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 9.99 (s, 1H), 7.82 (d, J = 4.0 Hz, 1H), 7.46 (d, J = 3.5 Hz, 1H), 6.98 (d, J = 4.0 Hz, 2H), 6.32 (d, J =4.0 Hz, 2H), 2.65 (s, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 182.8, 159.4, 146.1, 143.6, 135.6, 134.1, 132.7, 131.8, 130.3, 120.4, 15.2; HRMS (ESI+): m/z calcd. for  $C_{16}H_{14}BF_2N_2OS[M+H]^+$ , 331.0885; found 331.0886.

Synthesis of BODIPY 2f (Scheme 3).

#### The Journal of Organic Chemistry





**BODIPY D**. To a solution of **B** (50 mg, 0.1879 mmol, 1.0 equiv.) in THF (3.0 mL) was added dropwise a solution of NBS (70 mg, 2.20 mmol, 2.1 equiv.) in THF (1.5 mL) at room temperature. The mixture was stirred at room

temperature for 1 h. The product was diluted with ethyl acetate (5.0 mL), washed with brine (2x10mL) and dried over MgSO<sub>4</sub>, and filtered. The solvent was removed in vacuo to provide the desired product as a dark pink solid (74 mg, 93% yield); mp 109 °C; TLC (15% EtOAc/hexanes,  $R_f = 0.6$ ); IR (KBr, cm<sup>-1</sup>): 3540 (w), 2929 (w), 1739 (m), 1532 (m), 1450 (m), 1372 (m), 1314 (w), 1243 (s), 1174 (m), 1141 (s), 1090 (m), 1011 (m), 895 (m), 678 (w); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.43 (s, 2H), 2.82 (s, 3H), 2.6 (s, 6H); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>CN),  $\delta$ : 154.8, 145.6, 133.8, 128.3, 108.9, 21.7, 13.6; HRMS (ESI+): *m/z* calcd. for C<sub>12</sub>H<sub>12</sub>BBr<sub>2</sub>F<sub>2</sub>N<sub>2</sub>S [M+H]<sup>+</sup>, 424.9125; found 424.9121.



According to GP1. **D** (100 mg, 0.2359 mmol, 1.0 equiv.), 4formylphenylboronic acid (88 mg, 0.5897 mmol, 2.5 equiv.), CuTC (135 mg, 0.7077 mmol, 3.0 equiv.),  $Pd_2(dba)_3$  (5.4 mg, 0.0059 mmol, 2.5 mol%), and tri-2-furylphosphine (4.1 mg, 0.0018 mmol, 7.5 mol%). The desired product was obtained as dark purple crystals (102 mg, 90% yield); mp > 210 °C (subl.); TLC (30% EtOAc/hexanes,  $R_f = 0.6$ ); IR (KBr, cm<sup>-1</sup>): 3122 (w), 2836 (w), 2737 (w), 1703 (s), 1575 (s), 1559 (s), 1452 (m), 1246 (s), 1130 (s), 1004 (m), 988 (m), 823 (m), 485 (m); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  10.13 (s, 1H), 8.03 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 2H), 6.74 (s, 2H), 2.64 (s, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  191.2, 157.0, 140.2, 139.0, 137.8, 133.0, 131.0, 130.3, 129.8, 109.7, 13.7; HRMS (ESI+): *m/z* calcd. for C<sub>18</sub>H<sub>14</sub>BBr<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O [M+H]<sup>+</sup>, 482.9512; found 482.9506.

#### Synthesis of 2-formylBODIPYs (Scheme 4)





According to GP2. DMF (3.0 mL, 39.0 mmol, 218.5 equiv.), POCl<sub>3</sub> (3.0 mL, 32.0 mmol, 179.3 equiv.), *p*trifluoromethylphenylBODIPY (60 mg, 0.1785 mmol, 1.0 equiv.), DCE (20.0 mL). The desired product was obtained as a dark red crystals (26 mg, 40% yield); mp > 210 °C (dec.); TLC

(30% EtOAc/hexanes,  $R_f = 0.4$ ); IR (KBr, cm<sup>-1</sup>): 3109 (w), 2922 (m), 2851 (m), 1677 (s), 1544 (s), 1398 (s), 1329 (s), 1283 (m), 1171 (m), 1123 (m), 1098 (m), 976 (m), 915 (m), 855 (m), 740 (m), 718 (m), 649 (w); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.86 (s, 1H), 8.31 (s, 1H), 8.23 (s, 1H), 7.85 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 2H), 7.24 (s, 1H), 7.10 (d,

 J = 4.4 Hz, 1H), 6.76 (d, J = 4.4 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  184.8, 150.7, 147.4, 143.7, 137.1, 136.4, 134.7, 134.5, 133.6, 133.3, 132.2, 130.8, 128.7, 126.0 (q, <sup>3</sup>J<sub>CF</sub> = 3.7 Hz), 125.0, 122.3; HRMS (ESI+): *m/z* calcd. for C<sub>17</sub>H<sub>11</sub>BF<sub>5</sub>N<sub>2</sub>O [M+H]<sup>+</sup>, 365.0882; found 365.0897.

## The Passerini reaction (Scheme 5).



According to GP3: **2a** (30 mg, 0.1013 mmol, 1.0 equiv.), benzoic acid (37 mg, 0.3039 mmol, 3.0 equiv.) and *tert*-butyl isocyanide (34.0  $\mu$ L, 0.3039 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a yellow solid (38 mg, 75 % yield); mp 220-222 °C; TLC (30 % EtOAc/hexanes, R<sub>f</sub> = 0.3); IR (KBr, cm<sup>-1</sup>): 3305 (m), 3079

(w), 2969 (w), 1727 (s), 1664 (s), 1556 (s), 1414 (s), 1387 (s), 1262 (s), 1112 (s), 1077 (s), 985 (w) 709 (m). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.13 (d, *J* = 7.5 Hz, 2H), 7.93 (s, 2H), 7.69 (d, *J* = 8.0 Hz, 2H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.53 (t, *J* = 7.8 Hz, 2H), 6.94 (d, *J* = 4.0 Hz, 2H), 6.53 (d, *J* = 3.0 Hz, 2H), 6.35 (s, 1H), 6.23 (br, 1H), 1.42 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  167.0, 164.8, 146.7, 144.5, 139.0, 135.0, 134.4, 134.1, 131.8, 130.9, 129.9, 129.2, 129.0, 127.6, 118.8, 75.5, 52.0, 28.9; HRMS (ESI+): *m/z* calcd. for C<sub>28</sub>H<sub>27</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>, 502.2113; found 502.2112.



According to GP3: **2b** (30 mg, 0.0926 mmol, 1.0 equiv.), benzoic acid (34 mg, 0.2778 mmol, 3.0 equiv.) and *tert*-butyl

**ACS Paragon Plus Environment** 

isocyanide (31.0 µL, 0.2778 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as an orange solid (43 mg, 87 % yield); mp 201-203 °C; TLC (30 % EtOAc/hexanes,  $R_f = 0.4$ ); IR (KBr, cm<sup>-1</sup>): 3299 (m), 3102 (w), 2969 (m), 1723 (s), 1666 (s), 1543 (s), 1413 (s), 1391 (s), 1259 (s), 1224 (s), 1080 (s), 973 (s), 839 (w), 767 (s), 758 (s), 718 (s). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.12 (d, *J* = 7.0 Hz, 2H), 7.66-7.63 (m, 3H), 7.53-7.50 (m, 4H), 6.71 (d, *J* = 4.0 Hz, 2H), 6.32 (s, 1H), 6.25 (d, *J* = 4.0 Hz, 2H), 6.19 (br, 1H), 2.64 (s, 6H), 1.41 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  167.1, 164.9, 158.0, 141.8, 138.0, 134.8, 134.6, 134.0, 130.8, 130.6, 129.9, 129.3, 128.9, 127.4, 119.6, 75.6, 51.9, 28.9, 15.0; HRMS (ESI+): *m/z* calcd. for C<sub>30</sub>H<sub>31</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>, 530.2426; found 530.2429.



According to GP3: **2c** (21 mg, 0.0596 mmol, 1.0 equiv.), benzoic acid (22 mg, 0.1789 mmol, 3.0 equiv.) and *tert*-butyl isocyanide (20.0  $\mu$ L, 0.1789 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as an orange solid (30 mg, 90 % yield); mp 166-168 °C; TLC (30 % EtOAc/hexanes, R<sub>f</sub> = 0.5); IR (KBr, cm<sup>-1</sup>): 3305 (m),

2971(m), 2935 (w), 1725 (s), 1663 (s), 1555 (s), 1439 (s), 1319 (s), 1260 (s), 1141 (s), 1033 (s), 983 (m), 885 (m), 710 (s); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.13 (d, *J* = 7.5 Hz, 2H), 7.66-7.63 (m, 3H), 7.54-7.51 (m, 4H), 6.74 (d, *J* = 4.0 Hz, 2H), 6.34-6.33 (m, 3H), 6.19 (br, 1H), 3.07 (q, *J* = 7.5 Hz, 4H), 1.42 (s, 9H), 1.34 (t, *J* = 7.6 Hz, 6H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  167.1, 164.9, 163.9, 142.2, 138.0, 134.9, 134.3, 134.0, 130.8, 1260 (s), 1141 (s), 1260 (s), 1260 (s), 1260 (s), 1141 (s), 1260 (s), 1

#### The Journal of Organic Chemistry

130.6, 129.9, 129.3, 129.0, 127.4, 117.5, 75.6, 51.9, 28.9, 22.2, 12.9; HRMS (ESI+): *m/z* calcd. for C<sub>32</sub>H<sub>35</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>, 558.2740; found 558.2738.



According to GP3: **2d** (20 mg, 0.0662 mmol, 1.0 equiv.), benzoic acid (24 mg, 0.1986 mmol, 3.0 equiv.) and *tert*-butyl isocyanide (23  $\mu$ L, 0.1986 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a red solid (30 mg, 89 % yield); mp 183-186 °C; TLC (30 % EtOAc/hexanes, R<sub>f</sub> = 0.3); IR (KBr, cm<sup>-1</sup>): 3299 (m), 3102

(w), 2969 (m), 1723 (s), 1666 (s), 1543 (s), 1413 (s), 1391 (s), 1259 (s), 1080 (s), 973 (s), 767 (s), 718 (s). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.12 (d, *J* = 7.0 Hz, 2H), 7.92 (s, 2H), 7.66 (t, *J* = 7.5 Hz, 1H), 7.53 (t, *J* = 7.8 Hz, 2H), 7.45 (d, *J* = 4.0 Hz, 1H), 7.36 (d, *J* = 4.0 Hz, 1H), 7.27 (d, *J* = 4.0 Hz, 2H), 6.56 (m, 3H), 6.18 (br, 1H), 1.43 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  165.8, 164.8, 144.3, 144.2, 139.0, 135.7, 134.4, 134.3, 132.7, 131.7, 130.0, 129.0, 128.8, 128.3, 118.8, 71.7, 52.2, 28.8; HRMS (ESI+): *m/z* calcd. for C<sub>26</sub>H<sub>25</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup>, 508.1677; found 508.1671.



According to GP3: **2e** (30 mg, 0.0908 mmol, 1.0 equiv.), benzoic acid (33 mg, 0.2726 mmol, 3.0 equiv.) and *tert*butyl isocyanide (31.0  $\mu$ L, 0.2726 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a red solid (37 mg, 76 % yield); mp 210-213 °C; TLC (30 % EtOAc/hexanes, R<sub>f</sub> = 0.4); IR (KBr, cm<sup>-1</sup>): 3278 (m), 3086 (w), 2966 (m), 2918 (m), 2850 (w), 1722 (s), 1665 (s), 1556 (s), 1492 (s), 1452 (s), 1275 (s), 1143 (s), 1090 (m), 1014 (s), 975 (s), 796 (s), 710 (s); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.11 (d, J = 7.5 Hz, 2H), 7.65 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.8 Hz, 2H), 7.32–7.30 (m, 2H), 7.05 (d, J = 4.0 Hz, 2H), 6.53 (s, 1H), 6.29 (d, J = 4.0 Hz, 2H), 6.13 (br, 1H), 2.64 (s, 6H), 1.42 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  166.0, 164.8, 158.2, 142.3, 136.0, 134.3, 134.2, 131.4, 130.6, 130.0, 129.0, 128.6, 128.0, 119.7, 71.8, 52.1, 28.8, 15.1; HRMS (ESI+): *m*/*z* calcd. for C<sub>28</sub>H<sub>29</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup>, 536.1990; found 536.1992.



According to GP3: **2f** (30 mg, 0.0622 mmol, 1.0 equiv.), benzoic acid (23 mg, 0.1866 mmol, 3.0 equiv.) and *tert*butyl isocyanide (21.0  $\mu$ L, 0.1866 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a fuchsia solid (36 mg, 84 % yield); mp > 280 °C (subl.); TLC (30 % EtOAc/hexanes, R<sub>f</sub> = 0.6); IR (KBr,

cm<sup>-1</sup>): 3433 (w), 3120 (w), 2967 (w), 1733(s), 1684 (s), 1546 (s), 1451 (s), 1246 (s), 1146 (s), 1011 (s), 715 (m), 489 (m); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.13 (d, *J* = 7.0 Hz, 2H), 7.68-7.64 (m, 3H), 7.53 (t, *J*= 7.8 Hz, 2H), 7.49 (d, *J*= 8.5 Hz, 2H), 6.81 (s, 2H), 6.33 (s, 1H), 6.23 (br, 1H), 2.62 (s, 6H), 1.42 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  166.9, 164.8, 156.2, 141.6, 138.9, 134.1, 133.7, 133.2, 130.7, 130.6, 129.9, 129.2, 129.0, 127.7, 109.2, 75.5, 52.0, 28.9, 13.6; HRMS (ESI+): *m/z* calcd. for C<sub>30</sub>H<sub>29</sub>BBr<sub>2</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>, 686.0618; found 686.0617.



According to GP3: **3a** (29 mg, 0.0979 mmol, 1.0 equiv.), benzoic acid (36 mg, 0.2937 mmol, 3.0 equiv.) and *tert*butyl isocyanide (33.0  $\mu$ L, 0.2937 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as an orange solid (33 mg, 68 % yield); mp 172-

174 °C; TLC (30 % EtOAc/hexanes,  $R_f = 0.3$ ); IR (KBr, cm<sup>-1</sup>): 3394 (w), 2969 (w), 1717 (s), 1687 (s), 1552 (s), 1384 (m), 1259 (s), 1096 (s), 979 (w), 725 (w), 716 (w); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (d, J = 7.2 Hz, 2H), 7.99 (d, J = 4.4 Hz, 2H), 7.64-7.45 (m, 8 H), 7.04 (s, 1H), 6.98 (d, J = 4.4 Hz, 1H), 6.58 (d, J = 3.2 Hz, 1H), 6.23 (s, 1H), 6.04 (br, 1H), 1.36 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  166.8, 165.0, 148.2, 145.7, 141.6, 135.6, 134.6, 134.0, 133.8, 133.6, 132.8, 131.2, 130.7, 130.3, 129.9, 129.1, 128.9, 128.7, 128.6, 119.4, 70.2, 51.8, 28.8; HRMS (ESI+): m/z calcd. for C<sub>28</sub>H<sub>26</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Na [M+Na]<sup>+</sup>, 524.1932; found 524.1934.



According to GP3: **3b** (30 mg, 0.0887 mmol, 1.0 equiv.), benzoic acid (33 mg, 0.2661 mmol, 3.0 equiv.) and *tert*butyl isocyanide (30.0  $\mu$ L, 0.2661 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a yellow solid (44 mg, 91 % yield); mp 117-

120 °C; TLC (30 % EtOAc/hexanes,  $R_f = 0.5$ ); IR (KBr, cm<sup>-1</sup>): 3403 (w), 2973 (w), 2921 (w), 1721 (m), 1694 (m), 1563 (s), 1386 (m), 1364 (m), 1258 (s), 1104 (s), 1069 (m), 706 (m); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (d, J = 7.0 Hz, 2H), 7.95 (s, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.7 Hz, 2H), 6.94 (s, 2H), 6.78 (s, 1H), 6.73 (d, J = 4.0 Hz, 1H),

6.50 (d, J = 3.5 Hz, 1H), 6.15 (s, 1H), 5.91 (br, 1H), 2.36 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 1.34 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  166.8,165.0, 148.7, 145.9, 141.8, 139.2, 136.4, 136.3, 136.2, 135.1, 133.9, 131.4, 130.0, 129.5, 129.2,128.9, 128.5, 128.4, 128.3, 119.4, 70.3, 51.8, 28.8, 21.2, 20.2, 20.1; HRMS (ESI+): m/z calcd. for C<sub>31</sub>H<sub>32</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Na [M+Na]<sup>+</sup>, 566.2402; found 566.2405.



According to GP3: **3c** (15 mg, 0.0400 mmol, 1.0 equiv.), benzoic acid (15 mg, 0.1200 mmol, 3.0 equiv.) and *tert*butyl isocyanide (14.0  $\mu$ L, 0.1200 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as an orange solid (9 mg, 40 % yield); mp 108-

110 °C; TLC (30 % EtOAc/hexanes,  $R_f = 0.4$ ); IR (KBr, cm<sup>-1</sup>): 3400 (w), 2968 (w), 1724 (m), 1692 (m), 1570 (s), 1545 (m), 1385 (m), 1364 (m), 1258 (s), 1101 (s), 912 (w), 711 (w); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (d, J = 7.5 Hz, 2H), 7.99 (s, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.01 (s, 1H), 6.94 (d, J = 3.5 Hz, 1H), 6.59 (d, J = 3.5 Hz, 1H), 6.22 (s, 1H), 6.02 (br, 1H), 1.37 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  166.7, 165.0, 146.6, 146.1, 142.2, 135.4, 134.4, 134.0, 132.5, 132.4, 132.1, 132.0, 129.9, 129.6, 129.2, 128.9, 126.0, 119.6, 70.2, 51.9, 28.8; HRMS (ESI+): *m/z* calcd. for C<sub>28</sub>H<sub>25</sub>BBrF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Na [M+Na]<sup>+</sup>, 602.1038; found 602.1041.



According to GP3: **3d** (20 mg, 0.0549 mmol, 1.0 equiv.), benzoic acid (20 mg, 0.1648 mmol, 3.0 equiv.) and *tert*-

ACS Paragon Plus Environment

butyl isocyanide (19.0 μL, 0.1648 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as an orange solid (12 mg, 38 % yield); mp 193-196 °C; TLC (30 % EtOAc/hexanes,  $R_f = 0.5$ ); IR (KBr, cm<sup>-1</sup>): 3393 (w), 2968 (w), 1723 (m), 1681 (m), 1553 (s), 1325 (m), 1258 (s), 1100 (s), 915 (w), 715 (m); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.06 (d, J = 7.5 Hz, 2H), 8.02 (s, 2H), 7.80 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 6.63 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 6.97 (s, 1H), 6.91 (d, J = 4.0 Hz, 1H), 6.60 (d, J = 3.5 Hz, 1H), 6.22 (s, 1H), 6.04 (br, 1H), 1.36 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 166.6, 165.0, 146.6, 145.9, 142.6, 137.0, 135.5, 134.5, 134.0, 132.4, 130.8, 129.9, 129.6, 129.1, 129.0, 125.8, 125.7, 124.9, 119.9, 70.1, 51.9, 28.8; HRMS (ESI+): *m/z* calcd. for C<sub>29</sub>H<sub>25</sub>BF<sub>5</sub>N<sub>3</sub>O<sub>3</sub>Na [M+Na]<sup>+</sup>, 592.1806, found 592.1807.



According to GP3: **3e** (15 mg, 0.0500 mmol, 1.0 equiv.), benzoic acid (18 mg, 0.1500 mmol, 3.0 equiv.) and *tert*butyl isocyanide (17.0  $\mu$ L, 0.1500 mmol, 3.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (1.0 mL/1:1). The desired product was obtained as a red solid (15 mg, 60 % yield); mp > 60 °C

(dec.); TLC (30 % EtOAc/hexanes,  $R_f = 0.3$ ); IR (KBr, cm<sup>-1</sup>): 3400 (w), 2965 (w), 1723 (m), 1682 (m), 1546 (s), 1409 (s), 1388 (s), 1260 (s), 1105 (s), 975 (w), 711 (m); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.07 (d, J = 8.0 Hz, 2H), 7.97 (s, 2H), 7.73 (d, J = 5.0 Hz, 1H), 7.63 (t, J = 7.2 Hz, 1H), 7.58 (d, J = 3.5 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 7.38 (s, 1H), 7.32 (d, J = 3.5 Hz, 1H), 7.28 (d, J = 4.0 Hz, 1H), 6.61 (d, J = 3.5 Hz, 1 H), 6.25 (s, 1H), 6.03 (br, 1H), 1.38 (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  166.8, 165.0, 145.3, 141.4, 140.4, 135.0, 134.5, 134.0, 133.6, 132.6, 132.1, 130.0, 129.8, 129.2, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.6, 128.9, 128.9, 128.6, 128.9, 128.9, 128.6, 128.9, 128.9, 128.6, 128.9, 128.9, 128.6, 128.9, 128.9, 128.9, 128.6, 128.9, 128.

119.3, 51.9, 28.8; HRMS (ESI+): *m/z* calcd. for C<sub>26</sub>H<sub>24</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>SNa [M+Na]<sup>+</sup>, 530.1496, found 530.1501.

**Supporting Information Available:** Copies of both <sup>1</sup>H and <sup>13</sup>C NMR spectra of all of the compounds in this paper, numerical documentation of the theoretical calculations. This material is available free of charge via the Internet at http://pubs.acs.org.

#### Acknowledgments

Financial support from the MINECO (MAT2014-51937-C3-03) and Gobierno Vasco (IT339-10 and IT912-16) of Spain are thanked. D. E. R.-O. and E. A.-M. thank CONACyT for graduate scholarship. We thank CONACyT (grants 129572, 123732, CB2011-166860, and PN2014-247109) for financial support. L. A. P.-G. and H. M. M.-M. wish to thank Sociedad Latinoamericana de Glicobiología A.C., and Universidad de Guanajuato (grant DAIP-529/2015). Donation of Biellman BODIPYs by Cuantico de Mexico (www.cuantico.mx) is kindly appreciated.

#### References

(1) . (a) Dömling, A.; Wang, W.; Wang, K. Chem. Rev. 2012, 112, 3083. (b) Dömling,
 A. Chem. Rev. 2006, 106, 17. (c) Shestopalov, A. M.; Shestopalov, A. A.;
 Rodinovskaya, L. A. Synthesis 2008, 0001. (d) Weber, L.; Illgen, K.; Michael Almstetter.
 M. Synlett 1999, 366. (e) Zhu, J. Eur. J. Org. Chem. 2003, 1133. (f) Dömling, A.; Ugi, I.
 Angew. Chem. Int. Ed. 2000, 39, 3168.

(2) Martinez-Ariza, G.; Ayaz, M.; Medda, F.; Hulme, C. J. Org. Chem. 2014, 79, 5153.

(3) Siddiqui, I. R.; Rai, P.; Srivastava, A.; Shamim, S. Tetrahedron Lett. 2014, 55,1159.

(4) Lv, L.; Zheng, S.; Cai, X.; Chen, Z.; Zhu, Q.; Liu, S. ACS Comb. Sci. 2013, 15, 183.

(5) Soleimani, E.; Ghorbani, S.; Ghasempour, H. R. Tetrahedron 2013, 69, 8511.

(6) Cai, Z.-J.; Wang, S.-Y.; Ji, S.-J. Org. Lett. 2012, 14, 6068.

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
10	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
22	
აა ე₄	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
53 E4	
54 77	
55	
56	
57	
58	
59	
60	

- (7) Wang, W.; Dömling, A. J. Comb. Chem. 2009, 11, 403.
- (8) Zhou, H.; Zhang, W.; Yan, B. J. Comb. Chem. 2010, 12, 206.
- (9) Rhoden, C. R. B.; Rivera, D. G.; Kreye, O.; Bauer, A.K.; Westermann, B.; Ludger A.
- Wessjohann, L. A. J. Comb. Chem. 2009, 11, 1078.
- (10) Sachdeva, H.; Dwivedi, D. Sci. World J. 2012, 1.
- (11) Vijesh, A. M.; Isloorb, A. M.; Peethambarc, S. K.; Shivanandad, K. N.; Arulmolia,
- T.; Isloore, N. A. Eur. J. Med. Chem. 2011, 46, 5591.
- (12) Chan, C. Y. K.; Tseng, N.-W.; Lam, J. W.Y.; Liu, J.; Kwok, R. T. K.; Ben Zhong Tang, B. Z. *Macromolecules* **2013**, *46*, 3246.
- (13) Padmaja, P.; Rao, G. K.; Indrasena, A.; Reddy, B. V. S.; Patel, N.; Shaik, A. B.; Reddy, N.; Dubeya, P. K.; Bhadra, M. P. *Org. Biomol. Chem.* **2015**, *13*, 1404.
- (14) (a) Hayek, A.; Bolze, F.; Bourgogne, C.; Baldeck, P. L.; Didier, P.; Arntz, Y.; Mély,
  Y.; Nicoud, J.-F. *Inorg. Chem.* 2009, 48, 9112. (b) Lin, W.; Long, L.; Wen Tan, W. *Chem. Commun.* 2010, 46, 1503. (c) de Silva, A. P.; Vance, T. P.; West, M. E. S.;
  Wright, G. D. Org. Biomol. Chem. 2008, 6, 2468. (d) Lavis, L. D.; Raines, R. T. ACS *Chem. Biol.*, 2008, 3, 142.
- (15) (a) Cui, S.-L.; Lin, X.-F.; Wang, Y.-G. J. Org. Chem. 2005, 70, 2866. (b) Cui, S.-L.; Lin, X.-F.; Wang, Y.-G. Org. Lett. 2006, 8, 4517.
- (16) Burchak, O. N.; Mugherli, L.; Ostuni, M.; Lacapere, J. J.; Balakirev, M. Y. J. Am. Chem. Soc. 2011, 133, 10058.
- (17) Rotaru, A. V.; Druta, I. D.; Oeser, T.; Müller, T. J. J. Helv. Chim. Acta 2005, 88, 1798.
- (18) Vázquez-Romero, A.; Kielland, N.; Arévalo, M. J.; Preciado, S.; Mellanby, R. J.;
- Feng, Y.; Lavilla, R.; Vendrell, M. J. Am. Chem. Soc. 2013, 135, 16018.
- (19) (a) Molecular Probes Inc., Eugene, Oregon, USA. (b) R. P. Haugland, *The Handbook. A Guide to Fluorescent Probes and Labeling Technologies*, 10th edn. Molecular Probes Inc., Eugene, Oregon, USA.
- (20) Banfi, L.; Riva, R. Org. React. 2005, 65, 1.
- (21) Bienaymé, H.; Bouzid, K. Angew. Chem., Int. Ed. 1998, 37, 2234.
- (22) Ugi, I.; Steinbruckner, C. Angew. Chem. 1960, 72, 267.

(23) Alternatively, **A-C** can be prepared according to: Goud, T. V.; Tutar, A.; Biellmann, J.-F. *Tetrahedron* **2006**, *62*, 5084.

(24) (a) Peña-Cabrera, E.; Aguilar-Aguilar, A.; Gonzalez-Dominguez, M.; Lager, E.; Zamudio-Vazquez, R.; Godoy-Vargas, J.; Villanueva-García, F. *Org. Lett.* 2007, *9*, 3985.
(b) Betancourt-Mendiola, L.; Valois-Escamilla, I. ; Arbeloa, T.; Bañuelos, J.; López Arbeloa, I.; Flores-Rizo, J. O.; Hu, R.; Lager, E.; Gómez-Durán, C. F. A.; Belmonte-Vázquez, J. L.; Martínez-González, M. R.; Arroyo, I. J.; Osorio-Martínez, C. A.; Alvarado-Martínez, E.; Urías-Benavides, A.; Gutiérrez-Ramos, B. D.; Tang, B. Z.; Peña-Cabrera, E. *J. Org. Chem.* 2015, *80*, 5771.

(25) (a) Jiao , L.; Yu, C.; Li, J.; Wang, Z.; Wu, M.; Hao, E. J. Org. Chem. 2009, 74, 7525. (b) Zhang, J.; Zhu, S.; Valenzano, L.; Luo, F.-T.; Liu, H. RSC Advances 2013, 3, 68. (c) Zhu, S.; Bi, J.; Vegesna, G.; Zhang, J.; Luo, F.-T.; Valenzano, L.; Liu, H. RSC Advances 2013, 3, 4793.

(26) Gómez-Durán, C. F. A.; Esnal, I.; Valois-Escamilla, I.; Urías-Benavides, A.;
Bañuelos, J.; López Arbeloa, I.; García-Moreno, I.; Peña-Cabrera, E. *Chemistry Eur. J.* **2016**, *22*, 1048.

(27) (a) Li, F.; Yang, S. I.; Ciringh, Y.; Seth, J.; Martin III, C. H.; Singh, D. L.; Kim, D.;
Birge, R. R.; Bocian, D. F.; Holten, D.; Lindsey, J. S. *J. Am. Chem. Soc.* 1998, *120*, 10001. (b) Kee, H. L.; Kirmaier, C.; Yu, L.; Thamyongkit, P.; Youngblood, W. J.;
Calder, M. E.; Ramos, L.; Noll, B. C.; Bocian, D. F.; Scheidt, W. R.; Birge, R. R.,
Lindsey, J. S.; Holten, D. *J. Phys. Chem. B* 2005, *109*, 20433. (c) Alamiry, M. A. H.;
Benniston, A. C.; Copley, G.; Elliott, K. J.; Harriman, A.; Stewart, B.; Zhi, Y. G. *Chem.*

(28) (a) Badre, S.; Monnier, V.; Meallet-Renault, R.; Dumas-Verdes, C.; Schmidt, E. Y.;
Mikhaleva, A.; Laurent, G.; Levi, G.; Ibañez, A.; Trofimov, B. A. J. Photochem.
Photobiol. A 2006, 183, 238. (b) Zheng, Q.; Xu, G.; Prasad, P. N. Chem. Eur. J. 2008, 14, 5812.

(29) (a) Cui, A. Peng, X.; Fan, J.; Chen, X.; Wu, Y.; Guo, B. J. Photochem. Photobiol. A
2007, 186, 85. (b) Mukherjee, S.; Thilagar, P. RSC Adv. 2015, 5, 2706.

(30) (a) Sabatini, R. P.; McCormick, T. M.; Lazarides, T.; Wilson, K. C.; Eisenberg, R.; McCamant, D. W. J. Phys. Chem . Lett. 2011, 2, 223. (b) Lakshmi, V.; Ravikanth, M.

Dalton Trans. 2012, 41, 5903. (c) Zhang, X. F., Yang, X.; Niu, K.; Geng, H. J. Photochem. Photobiol. A 2014, 285, 16.

(31) Durán-Sampedro, G.; Agarrabeitia, A. R.; García-Moreno, I.; Costela, A.; Bañuelos, J.; Arbeloa, T.; López Arbeloa, I.; Chiara, J. L.; Ortiz, M. J. *Eur, J. Org. Chem.* 2012, 6335.

(32) (a) Chen,Y.; Zhao, J.; Guo, H.; Li, Q. J. Org. Chem. 2012, 77, 2192. (b) Poirel, A.;
De Nicola, A.; Ziessel, R. Org. Lett. 2012, 14, 5696. (c) Yang, Y.; Guo. Q.; Chen. H.;
Zhou, Z.; Guo, Z.; Shen, Z. Chem. Commun. 2013, 49, 3940.

(33) (a) Kim, K.; Jo, C.; Easwaramoorthi, S.; Sung, J.; Kim, D. H.; Churchill, D. G. *Inorg. Chem.* 2010, *49*, 48881. (b) Collado, D.; Casado, J.; Rodriguez, S.; López, J. T.; Suau, R.; Pérez-Inestrosa, E.; Pappenfus, T. M.; Raposo, M. M. M. *Chem. Eur. J.* 2011, *17*, 498.

(34) Benniston, A. C.; Clift, S.; Hagon, J.; Lemmetyinen, H.; Tkachenko, N. V.; Clegg, W.; Harrington, R. W. *ChemPhysChem* 2012, *13*, 3672.

(35) Dias de Rezende, L. C.; Menezes Vaidergorn, M.; Biazzotto Moraes, J. C.; Da Silva Emery, F. *J. Fluoresc.* **2014**, *24*, 257.

(36) Grabowski, Z. R.; Rotkiewicz, Rettig, W. Chem. Rev. 2003, 103, 3899.

(37) Pruzanski, W.; Saito, S. Inflammation 1988, 12, 87.

(38) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, 62, 7512.

(39) (a) For compound 2a see ref. 24a. (b) Miao, Q.; Shin, J. Y.; Patrick, B. O.; Dolphin, D. *Chem. Commun.* 2009, 2541 (for compound 2b). (c) For compound 2c see ref. 24b. (d) Melanson, J. A.; Smithen, D. A.; Cameron, S. T.; Thompson, A. *Can. J. Chem.* 2014, *92*, 688. (e) Kee, H. L.; Kirmaier, C.; Yu, L.; Thamyongkit, P.; Youngblood, W. J.; Calder, M. E.; Ramos, L.; Noll, B. C.; Bocian, D. F.; Scheidt, W. R.; Birge, R. R.; Lindsey, J. S.; Holten D. *J. Phys. Chem. B*, 2005, *109*, 20433. (f) Yu, C.; Jiao, L.; Yin, H.; Zhou, J.; Pang, W.; Wu, Y.; Wang, Z.; Yang, G.; Hao, E. *Eur. J. Org. Chem.* 2011, *28*, 5460 (for compounds 3a-c and 3e).

(40) Zhang, S.; Zhang, D.; Liebeskind, L. S. *J. Org. Chem.* **1997**, *62*, 2312. Cu(I)TC is also commercially available.

(41) Endres, S.; Ghorbani, R.; Lonnemann, G.; van der Meer, J. W.; Dinarello, C.A. *Clin Immunol Immunopathol* **1988**, *49*, 424.

(42) Netea, M.G.; Nold-Petry, C.A.; Nold, M.F.; Joosten, L. A. B.; Opitz, B.; van del Meer, J. H. M., van de Veerdonk, F. L.; Ferwerda, G.; Heinhuis, B.; Devesa, I.; Funk, C. J.; Mason, R. J.; Kullberg, B. J.; Rubartelli, A.; van der Meer, J. W. M.; Dinarello, C. A. *Blood* 2009, *113*, 2324.

TOC



6 examples, 76-90% 5 examples, 38-91% FLUORESCENT PASSERINI ADDUCTS